# Biogen (BIIB) financials

Biogen reported revenue of $9.89 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), up 2.2% from fiscal 2024. Net income was $1.29 billion and diluted earnings per share $8.79.

In its latest reported quarter, the third quarter of fiscal 2026 (the three months to 30 Sep 2026), revenue was $2.80 billion, up 10.6% from a year earlier.

Source: Biogen's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 28 Oct 2026. Amounts in USD. Page: https://aapwire.com/stocks/BIIB. Retrieved 2026-11-16.

## Latest results: Q3 FY2026

Biogen reported revenue of $2.80 billion, up 10.6% from a year earlier, net income of −$20.6 million and diluted earnings per share of −$0.14 against $3.17 for the third quarter of fiscal 2026 (the three months to 30 Sep 2026).

From its quarterly report, filed 28 Oct 2026.

| Measure | Q3 FY2026 | Q3 FY2025 | Change |
| --- | ---: | ---: | ---: |
| Revenue | $2.80B | $2.53B | +10.6% |
| Gross profit | $2.06B | $1.86B | +10.5% |
| Gross margin | 73.3% | 73.4% | −0.1 pts |
| Operating income | −$9.00M | $557.3M | — |
| Operating margin | −0.3% | 22.0% | −22.3 pts |
| Net income | −$20.60M | $466.5M | — |
| Diluted EPS | −$0.14 | $3.17 | — |
| Operating cash flow | $640.8M | $1.27B | −49.6% |
| Capital expenditure | $40.40M | $46.20M | −12.6% |
| Free cash flow | $600.4M | $1.23B | −51.0% |

Page: https://aapwire.com/stocks/BIIB/earnings

## Annual figures (fiscal years)

| Measure | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $11.45B | $12.27B | $13.45B | $14.38B | $13.44B | $10.98B | $10.17B | $9.84B | $9.68B | $9.89B |
| Revenue growth | +6.4% | +7.2% | +9.6% | +6.9% | −6.5% | −18.3% | −7.4% | −3.3% | −1.6% | +2.2% |
| Gross profit | $9.97B | $10.64B | $11.64B | $12.42B | $11.64B | $8.87B | $7.90B | $7.30B | $7.37B | $7.49B |
| Operating income | $5.15B | $5.35B | $5.89B | $7.04B | $4.55B | $2.84B | $3.84B | $1.61B | $2.25B | $1.86B |
| Net income | $3.70B | $2.54B | $4.43B | $5.89B | $4.00B | $1.56B | $3.05B | $1.16B | $1.63B | $1.29B |
| Diluted EPS | $16.93 | $11.92 | $21.58 | $31.42 | $24.80 | $10.40 | $20.87 | $7.97 | $11.18 | $8.79 |
| Operating cash flow | $4.59B | $4.55B | $6.19B | $7.08B | $4.23B | $3.64B | $1.38B | $1.55B | $2.88B | $2.20B |
| Capital expenditure | $616.1M | $867.4M | $770.6M | $514.5M | $424.8M | $258.1M | $240.3M | $277.0M | $153.7M | $153.8M |
| Free cash flow | $3.97B | $3.68B | $5.42B | $6.56B | $3.81B | $3.38B | $1.14B | $1.27B | $2.72B | $2.05B |
| Gross margin | 87.1% | 86.7% | 86.5% | 86.4% | 86.6% | 80.8% | 77.6% | 74.2% | 76.1% | 75.7% |
| Operating margin | 45.0% | 43.6% | 43.8% | 49.0% | 33.8% | 25.9% | 37.7% | 16.4% | 23.2% | 18.8% |
| Net margin | 32.3% | 20.7% | 32.9% | 41.0% | 29.8% | 14.2% | 29.9% | 11.8% | 16.9% | 13.1% |
| Cash and equivalents | $2.33B | $1.57B | $1.22B | $2.91B | $1.33B | $2.26B | $3.42B | $1.05B | $2.38B | $3.01B |
| Total debt | $6.52B | $5.94B | $5.94B | $4.95B | $7.91B | $6.69B | $6.71B | $7.28B | $4.97B | $6.66B |
| Shareholders' equity | $12.14B | $12.61B | $13.04B | $13.34B | $10.70B | $10.90B | $13.40B | $14.80B | $16.72B | $18.26B |
| Diluted shares | 219M | 213M | 205M | 187M | 161M | 150M | 146M | 146M | 146M | 147M |

## Quarterly figures (last eight fiscal quarters)

| Measure | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $2.45B | $2.43B | $2.65B | $2.53B | $2.28B | $2.48B | $2.74B | $2.80B |
| Revenue, year on year | +2.9% | +6.1% | +7.3% | +2.8% | −7.1% | +1.9% | +3.4% | +10.6% |
| Gross margin | 76.2% | 74.1% | 77.1% | 73.4% | 78.3% | 73.3% | 71.6% | 73.3% |
| Operating income | $635.1M | $311.2M | $744.0M | $557.3M | $249.6M | $377.7M | $132.4M | −$9.00M |
| Net income | $266.7M | $240.5M | $634.8M | $466.5M | −$48.90M | $319.5M | $97.50M | −$20.60M |
| Diluted EPS | $1.83 | $1.64 | $4.33 | $3.17 | −$0.33 | $2.15 | $0.66 | −$0.14 |
| Free cash flow | $721.6M | $222.2M | $134.3M | $1.23B | $468.0M | $594.3M | $408.0M | $600.4M |

## Operating KPIs

| KPI | Latest | Period | Change on a year |
| --- | ---: | --- | --- |
| [Product revenue, net revenue](https://aapwire.com/stocks/BIIB/kpi/product-revenue-net-revenue) | $2.1B | quarter to 30 Sep 2026 | up 13.1% |
| [MS Product Revenues](https://aapwire.com/stocks/BIIB/kpi/ms-product-revenues) | $919.3M | quarter to 30 Sep 2026 | down 13.4% |
| [Rare Disease Product Revenue](https://aapwire.com/stocks/BIIB/kpi/rare-disease-product-revenue) | $676.3M | quarter to 30 Sep 2026 | up 26.8% |
| [Revenue from anti-CD20 therapeutic programs revenue](https://aapwire.com/stocks/BIIB/kpi/revenue-from-anti-cd20-therapeutic-programs-revenue) | $497.3M | quarter to 30 Sep 2026 | up 0.7% |
| [SPINRAZA revenue](https://aapwire.com/stocks/BIIB/kpi/spinraza-revenue) | $460.6M | quarter to 30 Sep 2026 | up 23.2% |
| [TYSABRI revenue](https://aapwire.com/stocks/BIIB/kpi/tysabri-revenue) | $437.1M | quarter to 30 Sep 2026 | up 1.2% |
| [Royalty Attributed To OCREVUS revenue](https://aapwire.com/stocks/BIIB/kpi/royalty-attributed-to-ocrevus-revenue) | $369.9M | quarter to 30 Sep 2026 | down 4.3% |
| [Fumarate revenue](https://aapwire.com/stocks/BIIB/kpi/fumarate-revenue) | $274.0M | quarter to 30 Sep 2026 | down 28.4% |
| [Specialized Immunology revenue](https://aapwire.com/stocks/BIIB/kpi/specialized-immunology-revenue) | $242.8M | quarter to 30 Sep 2026 | — |
| [Interferon revenue](https://aapwire.com/stocks/BIIB/kpi/interferon-revenue) | $208.2M | quarter to 30 Sep 2026 | down 15.7% |
| [VUMERITY revenue](https://aapwire.com/stocks/BIIB/kpi/vumerity-revenue) | $192.0M | quarter to 30 Sep 2026 | down 10.5% |
| [SYFOVRE revenue](https://aapwire.com/stocks/BIIB/kpi/syfovre-revenue) | $191.3M | quarter to 30 Sep 2026 | — |
| [SKYCLARYS revenue](https://aapwire.com/stocks/BIIB/kpi/skyclarys-revenue) | $178.2M | quarter to 30 Sep 2026 | up 34.1% |
| [Biosimilars revenue](https://aapwire.com/stocks/BIIB/kpi/biosimilars-revenue) | $165.9M | quarter to 30 Sep 2026 | down 15.7% |
| [AVONEX revenue](https://aapwire.com/stocks/BIIB/kpi/avonex-revenue) | $156.6M | quarter to 30 Sep 2026 | down 16.9% |
| [Contract manufacturing, royalty and other revenue](https://aapwire.com/stocks/BIIB/kpi/contract-manufacturing-royalty-and-other-revenue) | $149.7M | quarter to 30 Sep 2026 | down 1.0% |
| [Contract manufacturing revenue](https://aapwire.com/stocks/BIIB/kpi/contract-manufacturing-revenue) | $135.9M | quarter to 30 Sep 2026 | down 4.0% |
| [BENEPALI revenue](https://aapwire.com/stocks/BIIB/kpi/benepali-revenue) | $117.3M | quarter to 30 Sep 2026 | down 3.8% |
| [ZURZUVAE revenue](https://aapwire.com/stocks/BIIB/kpi/zurzuvae-revenue) | $84.4M | quarter to 30 Sep 2026 | up 52.6% |
| [TECFIDERA revenue](https://aapwire.com/stocks/BIIB/kpi/tecfidera-revenue) | $82.0M | quarter to 30 Sep 2026 | down 51.2% |
| [Alzheimer's Collaboration revenue](https://aapwire.com/stocks/BIIB/kpi/alzheimer-s-collaboration-revenue) | $68.4M | quarter to 30 Sep 2026 | up 60.2% |
| [PLEGRIDY revenue](https://aapwire.com/stocks/BIIB/kpi/plegridy-revenue) | $51.6M | quarter to 30 Sep 2026 | down 11.6% |
| [EMPAVELI revenue](https://aapwire.com/stocks/BIIB/kpi/empaveli-revenue) | $51.5M | quarter to 30 Sep 2026 | — |
| [IMRALDI revenue](https://aapwire.com/stocks/BIIB/kpi/imraldi-revenue) | $42.0M | quarter to 30 Sep 2026 | down 20.2% |
| [QALSODY revenue](https://aapwire.com/stocks/BIIB/kpi/qalsody-revenue) | $37.5M | quarter to 30 Sep 2026 | up 42.0% |
| [Royalty and other revenue](https://aapwire.com/stocks/BIIB/kpi/royalty-and-other-revenue) | $13.8M | quarter to 30 Sep 2026 | up 42.3% |
| [FLIXABI revenue](https://aapwire.com/stocks/BIIB/kpi/flixabi-revenue) | $6.4M | quarter to 30 Sep 2026 | down 58.2% |
| [BYOOVIZ revenue](https://aapwire.com/stocks/BIIB/kpi/byooviz-revenue) | $200,000 | quarter to 30 Sep 2026 | down 97.1% |

## Method

Each period is read from the report the company filed and checked against accounting identities; a figure that does not pass is left blank (—), never estimated. Free cash flow is operating cash flow less capital expenditure. Diluted EPS is as the company reported it, adjusted for later stock splits. Research information only, not investment advice.
